This Article Full Text Full Text (PDF) All Versions of this Article: 147/2/865    most recent Author Manuscript (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Qiao, L. Articles by Shao, J. Search for Related Content PubMed PubMed Citation Articles by Qiao, L. Articles by Shao, J.

Suppression of Adiponectin Gene Expression by Histone Deacetylase Inhibitor Valproic Acid

Graduate Center for Nutritional Sciences (L.Q., J.Sh.), University of Kentucky, Lexington, Kentucky 40536; and Departments of Microbiology (J.Sc.), University of Colorado Health Sciences Center, Denver, Colorado 80262

Address all correspondence and requests for reprints to: Jianhua Shao, M.D., Ph.D., Graduate Center for Nutritional Sciences, University of Kentucky, 900 South Limestone, Lexington, Kentucky 40536-0200. E-mail: JianhuaShao{at}uky.edu.

Valproic acid (VPA) has been used for the treatment of epilepsy and bipolar disorders for more than 30 yr. Obesity and insulin resistance are common side effects of VPA treatment. Adiponectin is an adipocyte-derived protein that plays an important role in controlling insulin sensitivity and glucose homeostasis. In this report, we examined the effects of VPA on adiponectin gene expression in C57BL/6J mice and in differentiated 3T3-L1 adipocytes. VPA treatment significantly decreased adiponectin protein and mRNA levels in both mice and 3T3-L1 adipocytes. The adipocyte study showed that VPA inhibited adiponectin gene expression in a dose- and time-dependent manner. Repression of adiponectin expression by VPA occurred at the transcription level and correlated with inhibition of histone deacetylase activity. Therapeutic concentrations of VPA increased overall histone acetylation and increased adiponectin promoter-driven luciferase expression in fibroblasts, but decreased adiponectin promoter activity in differentiated 3T3-L1 adipocytes. VPA treatment decreased adipogenic transcription factor CCAAT/enhancer binding protein- (C/EBP) levels and binding of C/EBP to the adiponectin promoter without altering the levels of peroxisome proliferator-activated receptor- and steroid regulatory element binding protein-1. Furthermore, VPA did not suppress adiponectin gene expression in C/EBP gene-deficient adipocytes that stably expressed exogenous peroxisome proliferator-activated receptor-2. Together, these results demonstrate that histone deacetylase inhibitor VPA suppresses adiponectin gene expression in mature adipocytes. The study also provides evidence that diminished C/EBP protein level and decreased binding at the adiponectin promoter mediate the inhibitory effects of VPA on adiponectin gene transcription.

This article has been cited by other articles:

				H. C. Cha, N. R. Oak, S. Kang, T.-A. Tran, S. Kobayashi, S.-H. Chiang, D. G. Tenen, and O. A. MacDougald Phosphorylation of CCAAT/Enhancer-binding Protein {alpha} Regulates GLUT4 Expression and Glucose Transport in Adipocytes J. Biol. Chem., June 27, 2008; 283(26): 18002 - 18011. [Abstract] [Full Text] [PDF]

				L. Qiao, C. Zou, P. Shao, J. Schaack, P. F. Johnson, and J. Shao Transcriptional Regulation of Fatty Acid Translocase/CD36 Expression by CCAAT/Enhancer-binding Protein {alpha} J. Biol. Chem., April 4, 2008; 283(14): 8788 - 8795. [Abstract] [Full Text] [PDF]

				H. V. Lin, J.-Y. Kim, A. Pocai, L. Rossetti, L. Shapiro, P. E. Scherer, and D. Accili Adiponectin Resistance Exacerbates Insulin Resistance in Insulin Receptor Transgenic/Knockout Mice Diabetes, August 1, 2007; 56(8): 1969 - 1976. [Abstract] [Full Text] [PDF]